Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358449 · ClinicalTrials.gov registry record · Phase 2
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
A Phase 2 study of Oesophagitis, Eosinophilic, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT00358449: Completed Phase 2 study of Oesophagitis, Eosinophilic, sponsored by GlaxoSmithKline.
NCT00358449 is a Phase 2 study of Oesophagitis, Eosinophilic that has completed, run by GlaxoSmithKline. The registered enrollment target is 84 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00358449, a Phase 2 study of Oesophagitis, Eosinophilic, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis.
Primary Outcome
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event is defined as any untoward medical occurrence that, at any dose that Results in death, life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; a congenital anomaly/birth defect. Drug-related AE's were considered to have a
Conditions Studied
Interventions
- DRUG mepolizumab
Study Locations (20)
Indiana
- GSK Investigational Site - Evansville
- GSK Investigational Site - Indianapolis
Michigan
- GSK Investigational Site - Southfield
- GSK Investigational Site - Troy
Missouri
- GSK Investigational Site - Kansas City
- GSK Investigational Site - St Louis
Texas
- GSK Investigational Site - Dallas
- GSK Investigational Site - Dallas
Alabama
- GSK Investigational Site - Birmingham
California
- GSK Investigational Site - San Diego
Florida
- GSK Investigational Site - Tampa
Georgia
- GSK Investigational Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2006-09-11 |
| Est. Completion | 2008-11-25 |
| Phase | Phase 2 |
What the finished NCT00358449 record still lists
NCT00358449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Oesophagitis, Eosinophilic appearing as the primary indexed condition, and to 1 intervention - of which mepolizumab is the first listed.
NCT00358449 names 20 study sites across 16 states, led by Indiana, Michigan, Missouri.
Frequently Asked Questions
What is clinical trial NCT00358449 about?
NCT00358449 is a clinical study titled "Intravenous Mepolizumab In Children With Eosinophilic Esophagitis". This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis.
What is the current status of trial NCT00358449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2006-09-11. Estimated completion is 2008-11-25.
What conditions does trial NCT00358449 study?
This clinical trial studies the following conditions: Oesophagitis, Eosinophilic.
What interventions are being tested in trial NCT00358449?
The interventions under investigation include: mepolizumab (DRUG).
Who is sponsoring clinical trial NCT00358449?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00358449 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00358449's enrollment target sits among peer trials
84 822nd of 2000 higher than 1,173 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI